Nachrichten zur Madrigal Pharmaceuticals Corp. Aktie

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Top-News – Aktie gewinnt 19 Prozent

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals kann am heutigen Handelstag einen satten Kurssprung hinlegen. Damit konnte nicht nur die jüngste…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Top-News – Aktie gewinnt 19 Prozent

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals kann am heutigen Handelstag einen satten Kurssprung hinlegen. Damit konnte nicht nur die jüngste…

Madrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings

…

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will…

Is Madrigal Pharmaceuticals Stock a Buy?

The biotech could be worth a lot more in 10 years.…

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering…

Is Madrigal Pharmaceuticals a Millionaire Maker?

Its revenue ramp-up is just starting, and its market looks lucrative.…

Is Madrigal Pharmaceuticals Stock a Buy?

The company could become a prominent player in the biotech industry, but that might take a while.…

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Eli Lilly just drizzled on Madrigal Pharmaceuticals parade.…

Madrigal Pharmaceuticals senior VP sells $570,000 in stock By Investing.com

Madrigal Pharmaceuticals senior VP sells $570,000 in stock…

Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked

…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Aktie mit Kurssprung – was ist da los?

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals entwickelt sich seit der Empfehlung des AKTIONÄR in der Rubrik „Hot-Stock der Woche“ in…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Aktie mit Kurssprung – was ist da los?

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals entwickelt sich seit der Empfehlung des AKTIONÄR in der Rubrik „Hot-Stock der Woche“ in…

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company…

Is Madrigal Pharmaceuticals Stock a Buy?

Its not the most prominent biotech, but it has an important claim to fame.…

Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript

…

US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Excitement grows as the FDAs first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Excitement grows as…

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

These businesses should see good times ahead.…

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

Both stocks are pretty risky, but one of them more so than the other.…

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? @themotleyfool #stocks $MDGL

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?…

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?…

Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming

Drugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI…

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

Madrigal has one key advantage over its two huge potential future rivals.…

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? @themotleyfool #stocks $MDGL $NVO $LLY

Madrigal has one key advantage over its two huge potential future rivals.…

Madrigal Pharmaceuticals upsizes public offering to $600 million By Investing.com

Madrigal Pharmaceuticals upsizes public offering to $600 million…

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on…

Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food…

Madrigal Pharmaceuticals shares target raised by JPM on FDA nod By Investing.com

Madrigal Pharmaceuticals shares target raised by JPM on FDA nod…

Citi lifts Madrigal Pharmaceuticals stock target to $389 By Investing.com

Citi lifts Madrigal Pharmaceuticals stock target to $389…

AKTIONÄR-Hot-Stock Madrigal: Kurssprung nach bahnbrechendem Erfolg – geht da noch mehr?

Besser hätte es für Madrigal Pharmaceuticals nicht laufen können. Die US-Zulassungsbehörde FDA hat die Zulassung für Resmetirom (Handelsname: Rezdiffra) zur…

AKTIONÄR-Hot-Stock Madrigal: Kurssprung nach bahnbrechendem Erfolg – geht da noch mehr?

Besser hätte es für Madrigal Pharmaceuticals nicht laufen können. Die US-Zulassungsbehörde FDA hat die Zulassung für Resmetirom (Handelsname: Rezdiffra) zur…

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Madrigal Pharmaceuticals (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.…

FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

The FDAs decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are…

Madrigal Pharmaceuticals: Hammer-Nachricht! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Madrigal Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Madrigal…

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering…

dpa-AFX ProFeed